Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
CGS 21680 hydrochloride (HB2097)
Description:Prototypic, selective A2A receptor agonist
Purity:>98%
-
-
(R,S)-CHPG sodium salt (HB0034)
Description:Selective mGluR5 agonist. Water soluble sodium salt.
Purity:>99%
-
-
-
CIQ (HB0197)
Description:GluN2C / GluN2D subunit selective NMDA receptor positive allosteric modulator
Purity:>98%
-
Citrinin (HB3839)
Description:Mitochondrial permeability transition pore (MPTP) activator
Purity:>97%
-
Clozapine (HB1607)
Description:Prototypic, atypical antipsychotic, binds to both serotonin and dopamine receptors
Purity:>99%
- Description:
Water soluble prototypic, atypical antipsychotic. Binds to both serotonin and dopamine receptors.
Purity:>98%
